Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Notes Payables: 2013-2023

Historic Notes Payables for Ocular Therapeutix (OCUL) over the last 5 years, with Jun 2023 value amounting to $2.1 million.

  • Ocular Therapeutix's Notes Payables was N/A to $2.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2020, which is N/A change from last year.
  • According to the latest figures from Q2 2023, Ocular Therapeutix's Notes Payables is $2.1 million, which was down 74.87% from $8.3 million recorded in Q1 2021.
  • Over the past 5 years, Ocular Therapeutix's Notes Payables peaked at $8.3 million during Q4 2020, and registered a low of $2.1 million during Q1 2020.
  • Its 2-year average for Notes Payables is $5.2 million, with a median of $5.2 million in 2021.
  • Data for Ocular Therapeutix's Notes Payables shows a peak YoY surged of 299.71% (in 2021) over the last 5 years.
  • Ocular Therapeutix's Notes Payables (Quarterly) stood at $8.3 million in 2020, then surged by 299.71% to $8.3 million in 2021, then reached $2.1 million in 2023.
  • Its Notes Payables stands at $2.1 million for Q2 2023, versus $8.3 million for Q1 2021 and $8.3 million for Q4 2020.